PECAM1 and chronic obstructive pulmonary disease: We found that COPD patients with higher levels of Syndecan-1 had higher rates of liberation from MV and that patients receiving NIV with higher levels of PECAM-1 had lower rates of liberation from MV (Additional File 3–5: Figs. S1–S3).